Filter
162
Text search:
ivermectin
Featured
Recommendations
23
New Publications
37
Language
Document type
No document type
61
Studies & Reports
37
Guidelines
36
Strategic & Response Plan
13
Manuals
6
Fact sheets
6
Training Material
1
Brochures
1
Infographics
1
Countries / Regions
Global
11
Uganda
7
Sierra Leone
6
Liberia
6
Ethiopia
6
Germany
5
Brazil
5
Latin America and the Carribbean
5
India
4
West and Central Africa
4
Middle East and North Africa
4
South Africa
3
Nigeria
2
Mozambique
2
East and Southern Africa
2
Africa
2
Congo, Democratic Republic of
1
Ghana
1
Philippines
1
South Sudan
1
Zambia
1
Kenya
1
Tanzania
1
Rwanda
1
Yemen
1
Paraguay
1
Solomon Islands
1
Russia
1
Authors & Publishers
Publication Years
Category
Countries
52
Clinical Guidelines
27
Public Health
13
Capacity Building
2
Women & Child Health
2
Key Resources
2
Pharmacy & Technologies
1
Toolboxes
NTDs
45
COVID-19
29
Pharmacy
9
Disability
3
Refugee
3
Mental Health
3
Caregiver
3
Ebola
2
Rapid Response
2
HIV
2
Social Ethics
2
Cholera
1
Conflict
1
AMR
1
doi: https://doi.org/10.1101/2020.11.30.20236570
Pre-Print Article
Onchocerciasis used to be an important public health problem in Africa, with over 37 million people infected and millions suffering from debilitating skin disease, terrible itching, impaired vision and
blindness. But the epidemiological situation has improved dramatically over the last two decades.
...
Ivermectin is an antiparasitic drug approved for the treatment of parasitic infections, including strongyloidiasis and onchocerciasis in humans. There is a reported increase in the use of ivermectin
...
A recent study informed that ivermectin was successfully used in vitro for the treatment of SARS-CoV-2 in experimentally infected cells and two preprint publications on observational clinical studies reported the apparent utility of
...
Better drug regimens for mass drug administration (MDA) could accelerate the Global Programme to Eliminate Lymphatic Filariasis (LF). This community study was designed to compare the safety and efficacy of MDA with IDA (ivermectin, diethylcarbamaz
...
3 March 2022
The WHO Therapeutics and COVID-19: living guideline contains the Organization’s most up-to-date recommendations for the use of therapeutics in the treatment of COVID-19. The latest version of this living guideline is available in pdf format (via the ‘Download’ button) and via an
...
Guideline ‒ Alternative mass drug administration regimens to eliminate lymphatic filariasis
recommended
Lymphatic filariasis is a vector-borne neglected tropical disease that causes damage of the lymphatic system and can lead to lymphoedema (elephantiasis) and hydrocele in infected individuals. The global baseline estimate of persons affected by lymphatic filariasis is 25 million men with hydrocele an
...
Coordinated Use of Anthelminthic Drugs in Control Interventions: a Manual for Health Professionals and Programme Managers
Tis first edition describes the standard operating procedures for health products for NTDs amenable to preventive chemotherapy and the medicines donated to treat them. These include albendazole for lymphatic filariasis and soil-transmitted helminthiases; azithromycin for trachoma and yaws; diethylca
...
A living WHO guideline on drugs for covid-19
recommended
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3379
Rapid Recommendation and visual graph. This is the fifth version (update 4) of the living guideline (BMJ 2020;370:m3379). When citing this article, please consider adding the update number and date of access for clarity. The publication of the RE
...
In response to the recent publication “Is onchocerciasis elimination in Africa feasible by 2025: a perspective based on lessons learnt from the African control programmes” by Dadzie et al., it is important to clarify and highlight the positive and unequivocal research and operational contributio
...
BMC Res Notes (2016) 9:182 DOI 10.1186/s13104-016-1993-7
The Strategic Plan of Action and Budget 2016-2025 for the elimination of onchocerciasisin countries was prepared based on the above dlrective for the consideration of IAF 18.The vision of the plan of action is to eliminate onchocerciasis in 80 percent of Africancountries. Implementation of the plan
...
The Onchocerciasis Control Programme in West Africa (OCP) undertook regional and large scale frght against onchocerciasis in West Africa in 1974 using a vector control strategy. By 2002 OCP had succeeded in eliminating the disease as a public health, socio-economic and development problem in 10 out
...
WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines.
Updated risk rates for hospital admission in patients with non-severe COVID-19
The guidance includes updated risk rates for
...
This twelfth version of the WHO living guideline now contains 19 recommendations. This latest update provides updated recommendations for remdesivir, addresses the use of combination therapy with corticosteroids, interleukin-6 (IL-6) receptor blockers and Janus kinase (JAK) inhibitors in patients wi
...
Several Public Health Services and general practitioners in the Netherlands observed an increase in scabies in the Netherlands. Since individual cases of scabies are not notifiable in the Netherlands, the epidemiological situation is mostly unknown. To investigate the scabies incidence in the Nether
...
L’ivermectine est un médicament antiparasitaire approuvé pour le traitement des infections parasitaires, y compris la strongyloïdose et l’onchocercose, chez l’être humain. Récemment, on a indiqué une augmentation de l’utilisation de l’ivermectine pour la prévention et le traitement
...
